GSK is paying $66 million upfront to license ... Tebipenem is the first oral drug in the carbapenem antibiotic class to reach late-stage development and, despite the desperate need for new ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

3 Year 85.66% 86.14% 34.23% 36.41% ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.